Bruce K. Walcheck
Affiliations: | University of Minnesota, Twin Cities, Minneapolis, MN |
Area:
Cell Biology, ImmunologyGoogle:
"Bruce Walcheck"Children
Sign in to add trainee| Polly E. Mattila | grad student | 2006 | UMN |
| Zhenya Ni | grad student | 2008 | UMN |
| Chunmei Long | grad student | 2012 | UMN |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Snyder KM, Dixon KJ, Davis Z, et al. (2023) iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting. Journal For Immunotherapy of Cancer. 11 |
| Cichocki F, Goodridge J, Bjordahl R, et al. (2022) Dual-antigen targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia. Blood |
| Hullsiek R, Li Y, Snyder KM, et al. (2022) Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells. Frontiers in Immunology. 13: 841859 |
| Snyder KM, McAloney CA, Montel JS, et al. (2020) Ectodomain shedding by ADAM17 (a disintegrin and metalloproteinase 17) in canine neutrophils. Veterinary Immunology and Immunopathology. 231: 110162 |
| Mishra HK, Ma J, Mendez D, et al. (2020) Blocking ADAM17 Function with a Monoclonal Antibody Improves Sepsis Survival in a Murine Model of Polymicrobial Sepsis. International Journal of Molecular Sciences. 21 |
| Goodridge JP, Reiser JW, Bjordahl R, et al. (2020) Abstract 2216: Combinational strategy targeting B cell malignancy using iPSC engineered CAR-NK (FT596) and CAR-T cell (FT819) platforms with therapeutic antibody to achieve an effective deep and durable response Immunology |
| Zhu H, Blum R, Bjordahl R, et al. (2019) Pluripotent stem cell-derived NK cells with high-affinity non-cleavable CD16a mediate improved anti-tumor activity. Blood |
| Pomeroy EJ, Hunzeker JT, Kluesner MG, et al. (2019) A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy. Molecular Therapy : the Journal of the American Society of Gene Therapy |
| Walcheck B, Wu J. (2019) iNK-CD64/16A cells: A promising approach for ADCC? Expert Opinion On Biological Therapy |
| Wu J, Mishra HK, Walcheck B. (2019) Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy. Journal of Leukocyte Biology |